09:44:06 EDT Wed 08 Jul 2020
Enter Symbol
or Name

Login ID:

Q:BGNE - BEIGENE LTD SPON ADS EACH REPR 13 ORD SH - Website unknown - click to update09:44:06 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BGNE - Q0.1198.62·201.830.1196.595.21,0604    210.35  114.4109:28:00Jul 0215 min RT 2¢

Recent Trades - All 4 today
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2020-07-02 07:00U:BGNENews ReleaseBeiGene to Host Investor Conference Call and Webcast to Discuss the Company ’s Early Development Pipeline and Research
2020-07-01 18:00U:BGNENews ReleaseBeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
2020-07-01 07:00U:BGNENews ReleaseBeiGene Announces Appointment of Angus Grant as Chief Business Executive
2020-06-30 19:30U:BGNENews ReleaseBeiGene Begins Commercializing XGEVA ® (Denosumab) in China
2020-06-22 09:00U:BGNENews ReleaseBeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
2020-06-19 00:28U:BGNENews ReleaseBeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
2020-06-18 07:30U:BGNENews ReleaseBeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA ® (Zanubrutinib) for the Treatment of Patients with Waldenstr ¶m ’s Macroglobulinemia
2020-06-12 02:30U:BGNENews ReleaseBeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress